Cargando…
Differential Effects of Sacubitril/Valsartan on Diastolic Function in Mice With Obesity-Related Metabolic Heart Disease
Mice with obesity and metabolic heart disease (MHD) due to a high-fat, high-sucrose diet were treated with placebo, a clinically relevant dose of sacubitril (SAC)/valsartan (VAL), or an equivalent dose of VAL for 4 months. There were striking differences between SAC/VAL and VAL with regard to: 1) di...
Autores principales: | Croteau, Dominique, Qin, Fuzhong, Chambers, Jordan M., Kallick, Ethan, Luptak, Ivan, Panagia, Marcello, Pimentel, David R., Siwik, Deborah A., Colucci, Wilson S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524781/ https://www.ncbi.nlm.nih.gov/pubmed/33015414 http://dx.doi.org/10.1016/j.jacbts.2020.07.006 |
Ejemplares similares
-
Effects of Sodium‐Glucose Linked Transporter 2 Inhibition With Ertugliflozin on Mitochondrial Function, Energetics, and Metabolic Gene Expression in the Presence and Absence of Diabetes Mellitus in Mice
por: Croteau, Dominique, et al.
Publicado: (2021) -
Decreased ATP production and myocardial contractile reserve in metabolic heart disease
por: Luptak, Ivan, et al.
Publicado: (2018) -
SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy
por: Croteau, Dominique, et al.
Publicado: (2023) -
Cardioprotective Effects of LCZ696 (Sacubitril/Valsartan) After Experimental Acute Myocardial Infarction
por: Ishii, Masanobu, et al.
Publicado: (2017) -
Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness
por: Aroor, Annayya R., et al.
Publicado: (2021)